Pradeep Malankar

TL;DR: Fractional doses of inactivated poliovirus vaccine administered intradermally at 2, 4, and 6 months, as compared with full doses of the vaccine given intramuscularly on the same schedule, induce similar levels of seroconversion but significantly lower titers.

TL;DR: A randomised, double-blind, controlled trial to assess the immunogenicity of a novel bivalent types 1 and 3 oral poliovirus vaccine and the superiority of monovalent type 2 OPV over trivalent OPV, and the non-inferiority of bivalent vaccine compared with mopV1 and mOPV3.

TL;DR: Accumulation of enough children to sustain the outbreak seems to have been due to previous success of the immunisation programme in reducing spread of endemic strains, suboptimum efficacy of OPV, and delay in completing the primary immunisation series until 7 months of age.

TL;DR: When given at birth, monovalent type 1 oral poliovirus vaccine is superior to trivalent oral Poliomyelitis vaccine in inducing humoral antibodies against type 1Poliovirus, overcoming high preexisting levels of maternally derived antibodies, and increasing the resistance to excretion of type 1 poliov virus after administration of a challenge dose.

TL;DR: A supplemental dose of IPV has excellent immunogenicity and leads to increases in the titer of antibodies against type 3 poliovirus, whereas supplemental doses of the oral vaccines do not have these effects.